NorthRock Partners’s BioNTech BNTX Stock Holding History

NorthRock Partners’s Portfolio BNTX Stock Details BNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-1,000	Closed	-$273K	–	341
2021 Q3	$273K	Hold	1,000	–	–	0.02%	228
2021 Q2	$224K	Buy	+1,000	New	+$189K	0.02%	226

Other funds holding BNTX

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Pendal Group Sydney, Australia $11.6B AUM 12.87% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

NorthRock Partners's BNTX Position: Q4 2021 in Review

NorthRock Partners sold out of BioNTech (BNTX) in Q4 2021, closing a stake of 1,000 shares — an estimated $273K sold.

NorthRock Partners first reported a position in BNTX in Q2 2021 and held it in 2 quarters. The position peaked at $273K in Q3 2021. 354 funds tracked by Wall St. Rank hold BNTX as of Q4 2021.

NorthRock Partners reported no remaining BioNTech position as of Q4 2021 after selling out during the quarter.
NorthRock Partners sold 1,000 BioNTech shares in Q4 2021, an estimated $273K.
NorthRock Partners first reported a position in BioNTech in Q2 2021 and held it in 2 quarters.
NorthRock Partners's BioNTech position peaked at $273K in Q3 2021.
354 funds tracked by Wall St. Rank held BioNTech as of Q4 2021.

Based on NorthRock Partners's 13F filing for Q4 2021, filed 7 Feb 2022.